Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BAY3546828 |
| Synonyms | |
| Therapy Description |
BAY3546828 comprises a monoclonal antibody that targets PSMA linked to the radionuclide Actinium-225, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 5047). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BAY3546828 | BAY 3546828|actinium-225-macropa-pelgifatamab|225Ac-pelgi|225Ac-pelgifatamab | PSMA Antibody 22 | BAY3546828 comprises a monoclonal antibody that targets PSMA linked to the radionuclide Actinium-225, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 5047). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06052306 | Phase I | BAY3546828 | A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | USA | SWE | NLD | ITA | GBR | FIN | CHE | CAN | 0 |